Trial reportThe Journal of clinical endocrinology and metabolism2026
Bisphenol A decreases peripheral insulin sensitivity in normal weight adults: a double-blind randomized controlled trial.
Trial report in The Journal of clinical endocrinology and metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
contextBisphenol A (BPA) is a synthetic chemical used in consumer goods that has been linked to type 2 diabetes in observational studies. No human experimental studies have examined whether BPA reduces peripheral insulin sensitivity. PURPOSE: To determine the effects of oral BPA administration on peripheral insulin sensitivity over 5 days.
methodsForty sedentary, but otherwise healthy adults (22 F, 18 M; 21.3 ± 2.1 year; 22.1 ± 2.3 kg/m2; 85% non-Hispanic White) completed a 2-day baseline energy-balanced diet low in BPA during which urine, blood, and peripheral insulin sensitivity via 120 minutes euglycemic hyperinsulinemic clamp technique (40 mU/m2/min; 90 mg/dL) were assessed. In a double-blind fashion, participants were randomly assigned to receive 5 days of oral BPA administration at 50 µg/kg body weight (BPA-50) or placebo (PL). All participants were fed the same energy-balanced diet. Outcomes were assessed using a two-way repeated-measures ANOVA adjusted for baseline sex, BMI, physical activity, and ethnicity.
resultsAfter treatment, urine BPA levels were significantly higher in BPA-50 compared to PL (+ 268 700 ± 63 983 vs PL: + 8893 ± 6786 pg/mL, P = .009). After treatment, body weight and fasting glucose were not statistically different between PL and BPA-50 (P > .05). However, BPA significantly decreased peripheral insulin sensitivity by 0.02 ± 0.01 mg/kg/min/uU/mL compared with an increase observed following PL by 0.02 ± 0.01 mg/kg/min/uU/mL (P = .01).
conclusionBPA administration decreased peripheral insulin sensitivity after 5 days. These data provide the first experimental evidence in humans that BPA administration may reduce insulin sensitivity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.